| Not Yet Recruiting | Prognosis of METTL-14 in Endometrial Carcinoma NCT06861855 | Assiut University | — |
| Recruiting | Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conser NCT07077876 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer NCT06917092 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors NCT06399757 | Apollo Therapeutics Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer NCT06066216 | Fujian Cancer Hospital | Phase 2 |
| Active Not Recruiting | Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer NCT05824481 | Sun Yat-sen University | Phase 2 |
| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Recruiting | A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma NCT05548296 | Acrivon Therapeutics | Phase 2 |
| Completed | V-Notes Hysterectomy in Patients With Endometrial cáncer Compared With Laparoscopic Surgery (Robotically Assis NCT07074067 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | N/A |
| Recruiting | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial NCT05112601 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | PErsonalized TReatment for Endometrial Carcinoma NCT05655260 | University of Helsinki | N/A |
| Terminated | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) NCT05001282 | Elucida Oncology | Phase 1 / Phase 2 |
| Completed | [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk E NCT04972682 | Moscow City Oncology Hospital No. 62 | N/A |
| Completed | Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies NCT04873206 | Sohag University | — |
| Active Not Recruiting | Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded t NCT04106414 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer NCT03836157 | University of Oklahoma | Phase 2 |
| Active Not Recruiting | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fall NCT03586661 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Evaluation of the Efficacy for Sentinel Lymph Node Policy in High-risk Endometrial Carcinoma NCT03716414 | Fudan University | — |
| Active Not Recruiting | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and C NCT03660826 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care NCT03460483 | Ohio State University Comprehensive Cancer Center | N/A |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Completed | Pembro/Carbo/Taxol in Endometrial Cancer NCT02549209 | Daniela Matei, MD | Phase 2 |
| Completed | Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines NCT03164590 | Assiut University | Phase 4 |
| Active Not Recruiting | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian NCT02208375 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or NCT02065687 | Gynecologic Oncology Group | Phase 2 / Phase 3 |
| Withdrawn | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometri NCT01943058 | University of Southern California | Phase 2 |
| Completed | Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Ear NCT01968317 | Xiaojun Chen | Phase 2 |
| Completed | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01935973 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01642082 | Gynecologic Oncology Group | Phase 2 |
| Completed | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01225887 | Gynecologic Oncology Group | Phase 2 |
| Completed | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer NCT01440998 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer NCT01210222 | Gynecologic Oncology Group | Phase 2 |
| Completed | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer NCT01307631 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Prognostic Biomarkers in Patients With Endometrial Cancer NCT01208467 | Gynecologic Oncology Group | — |
| Completed | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01132820 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Tr NCT01005329 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carbopla NCT00977574 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT01011933 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00888173 | Gynecologic Oncology Group | Phase 2 |
| Completed | Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00820898 | Gynecologic Oncology Group | Phase 2 |
| Completed | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithe NCT00814086 | Gynecologic Oncology Group | Phase 1 |
| Terminated | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer NCT01041027 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer NCT00478426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00095979 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer NCT00072176 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus NCT00064025 | Gynecologic Oncology Group | Phase 2 |
| Completed | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00025467 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer NCT00006089 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III NCT00006011 | Gynecologic Oncology Group | Phase 3 |
| Completed | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Ca NCT00005830 | Gynecologic Oncology Group | Phase 1 |
| Completed | Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus NCT00002706 | Gynecologic Oncology Group | Phase 3 |